Mandatory convertible bond   The issuance of a mandatory convertible bond with warrants attached provides Ikonisys with the liquidity needed for the global commercial roll-out strategy of the Ikoniscope20 and the further development of the microscopy platform into a state-of-the-art Artificial Intelligence system, in our view. In addition, Ik [ … ]

First sale of Ikoniscope20 Ikonisys has announced the first sale of its Ikoniscope20 microscope solution together with reagents. The sale is, in our view, a first proof that the commercialization strategy of migrating existing users of Ikonisys' former Ikoniscope Gen1 platform into users of the state-of-art Ikoniscope20 technology is correctly c [ … ]

New significant shareholder through convertible bond With the issuance of a de facto mandatory convertible bond, Ikonisys has, in our view, found a smart solution to one of its major problems: Funding the market entry of Ikoniscope20 in the US and Europe and funding the further development of the microscope platform into a state-of-the-art artif [ … ]

Important client-win in Italy After the first sale of the new-gen microscope, the Ikoniscope20, to one of the biggest genetic laboratories in Italy, we confirm our Buy rating for the shares of Ikonisys and our three-stage discounted cash flow entity model (primary valuation method) share price target of EUR 7.70. Ikonisys announced the sale an [ … ]

Restart of a technology leader in laboratory automation With a share price target of EUR 7.70 and an expected share price performance of 176.0%, we initiate research coverage on the shares of Ikonisys SA with a Buy rating. Our price target is derived from a threestage discounted cash flow entity model (primary valuation method), for which we ca [ … ]